Changes in Plasma Amyloid β 1–42 Peptide and Total Tau Protein from Normal Cognition to Severe-Stage Alzheimer’s Disease Using an Immunomagnetic Reduction Assay
Changes in Plasma Amyloid β 1–42 Peptide and Total Tau Protein from Normal Cognition to Severe-Stage Alzheimer’s Disease Using an Immunomagnetic Reduction Assay
Article Citation
Yang SY, Liu HC, Chiu MJ, Chang JF, Ho CS, Lee KH. (2011).
Changes in Plasma Amyloid β 1–42 Peptide and Total Tau Protein from Normal Cognition to Severe-Stage Alzheimer’s Disease Using an Immunomagnetic Reduction Assay.
PLOS ONE, 6(9): e23928.
Digital Object Identifier (DOI):
https://doi.org/10.1021/acsomega.6c00355
Clinical Stage Profiling
Investigating the clinical correlations of circulating Aβ1–42 and total Tau concentrations from healthy baselines through amnestic mild cognitive impairment (MCI) up to severe AD.
Analytical Performance
Utilizing high-precision magnetic nanostructure assay structures to detect ultra-low concentrations of target diagnostic neurodegenerative proteins in peripheral blood.
